Alnylam pharmaceuticals reports second quarter 2022 financial results and highlights recent period activity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the second quarter ended june 30, 2022 and reviewed recent business highlights. “we're pleased with our second quarter results which delivered strong growth in both patient demand and product revenues. a notable achievement in the quarter was the recent approval of amvuttra, which becomes our fifth rnai therapeutic approved
ALNY Ratings Summary
ALNY Quant Ranking